The International Consortium Investigating Neurocognition in Bipolar Disorder (ICONIC‐BD)

KEB has served on advisory boards for Neuralstem and Dainippon Sumitomo Pharma. CB has received grant support from Pfizer, Lundbeck and Takeda, and acts as a consultant for Boehringer Ingelheim, Lundbeck and Pfizer. PH has received consulting fees or travel reimbursements from Allergan, Alkermes, Akili, Biogen, Boehringer Ingelheim, Forum Pharma, Genentech (Roche Pharma), Intra-Cellular Therapies, Jazz Pharma, Lundbeck Pharma, Minerva Pharma,...